Key Drivers
- Strong Cash Flow
- High Leverage
- Thin Liquidity
AIAI Summary
TEVA is shifting from a pure generics turnaround to a “prove-it” growth story, where the key investment question is whether its rapidly growing innovative/neuroscience portfolio can sustain higher-value revenue and cash flow fast enough to offset heavy leverage, thin liquidity, and the market's skepticism toward 2026 guidance.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Flow
- •High Leverage
- •Thin Liquidity
TEVA is profitable and cash-generative, but high leverage, thin liquidity, and a demanding valuation mean the investment case depends more on sustained earnings and free cash flow than on balance-sheet strength.
Price Behavior
Key Price Behavior Insights:
- •Breakout hold
- •Momentum fade
- •Range test
TEVA remains modestly constructive over the last month after breaking above $31.20-$31.60, but fading momentum and failure to hold $35-$36 leave near-term upside capped.
Sharp breakout above the low-$31 area followed by a pullback from the $36.34 peak
Sentiment & News
Key News Insights:
- •Branded growth
- •Pipeline expansion
- •Valuation re-rating
Teva's Q1 beat, Emalex acquisition, and ongoing pipeline/buyback support underscore a clear turnaround toward a more innovative, higher-growth pharma profile.
The news is positive for Teva, as stronger earnings and strategic deal activity suggest improving fundamentals and continued upside if pipeline execution holds
Similar Companies in Healthcare
Other companies in the same sector with AI ratings